Document Library
Click the icons below to search through Pioneer’s reports and documents.
- 340B Drug Discounts: An Increasingly Dysfunctional Federal Program (32539)
- An Act advancing health care research and decision-making centered on patients and people with disabilities (12343)
- An “Impending Tsunami” in Mortality from Traditional Diseases? (8442)
- Antimicrobial Resistance: Learning from the current global health crisis to prevent another one (7783)
- Are Drug Prices Driving Healthcare Cost Growth? (20172)
- Comments on How Pharmacy Benefit Managers (PBMs) affect Smaller Pharmacies and Consumers (ID FTC-2022-0015-0001) (11900)
- Five Reasons Why Drug Rebates Are Harmful to Patients and to the Healthcare System (9069)
- Key Questions for Legislators on the Institute for Clinical and Economic Review (ICER) (13837)
- Looming Challenges for ICER in Assessing the Value of Rare Disease Therapies (779)
- Quality Adjusted Life Years (QALY): The Threat to Older Americans (7535)
- Testimony Against Price Control Legislation (10944)
- The Legality of QALY under the ADA (9211)
- The Negative Impact of COVID-19 Upon the Biopharmaceutical Sector (7596)
- The QALY and Cancer Treatments: An Ill-Advised Match (7966)
- Transparency in Retail Drug Prices: Easy to Obtain but Accuracy May Be Doubtful (13404)
- Will New England See Lower Prices from Drug Pricing Transparency Legislation? (19689)